ImmuneOnco Biopharmaceuticals (Shanghai) Inc. announced that the Group has successfully dosed the first patient for the Phase I clinical trial of IMM47 in Australia.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Equities
1541
CNE100006624
Biotechnology & Medical Research
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
14.46 HKD | -0.82% | -2.17% | -51.64% |
06-03 | ImmuneOnco Biopharmaceuticals Gets China's Phase 3 Trial Approval for Leukemia Drug | MT |
05-30 | ImmuneOnco Completes Filing with China Regulator for Conversion of H Shares | MT |
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-51.64% | 698M | |
+18.15% | 124B | |
+18.02% | 112B | |
+5.07% | 22.94B | |
-12.75% | 22.22B | |
-9.86% | 17.02B | |
-14.97% | 16.88B | |
-39.94% | 16.87B | |
+2.80% | 13.63B | |
+27.39% | 11.61B |
- Stock Market
- Equities
- 1541 Stock
- News ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
- Immuneonco Biopharmaceuticals Inc. Provides Updates on the Clinical Trial of Imm47